Open AccessRegulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer
Author(s) -
Jana Mašlanková,
Ivana Večurkovská,
Miroslava Rabajdová,
Jana Kaťuchová,
Milos Kicka,
Michala Gayova,
Vladimir Katuch
Publication year - 2022
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v28.i33.4744
Subject(s) - smad , cancer research , colorectal cancer , transforming growth factor , loss of heterozygosity , biology , signal transduction , transforming growth factor beta , angiogenesis , cancer , bioinformatics , genetics , gene , allele , endocrinology
According to data from 2020, Slovakia has long been among the top five countries with the highest incidence rate of colorectal cancer (CRC) worldwide, and the rate is continuing to rise every year. In approximately 80% of CRC cases, allelic loss (loss of heterozygosity, LOH) occurs in the long arm of chromosome 18q. The most important genes that can be silenced by 18q LOH or mutations are small mothers against decapentaplegic homolog (SMAD) 2 and SMAD4, which are intracellular mediators of transforming growth factor (TGF)-β superfamily signals. TGF-β plays an important role in the pro-oncogenic processes, including such properties as invasion, epithelial-mesenchymal transition (commonly known as EMT), promotion of angiogenesis, and immunomodulatory effects. Several recent studies have reported that activation of TGF-β signaling is related to drug resistance in CRC. Because the mechanisms of drug resistance are different between patients in different stages of CRC, personalized treatment is more effective. Therefore, knowledge of the activation and inhibition of factors that affect the TGF-β signaling pathway is very important.